Circle Pharma Moves Forward with Phase 1 Trial of CID-078
Circle Pharma Advances with CID-078 Clinical Trial
Circle Pharma, Inc., a clinical-stage biopharmaceutical company, specializes in pioneering macrocycle therapies. Recently, they announced a significant milestone—the first patient cohort was dosed in Phase 1 clinical trials of their innovative oral cyclin A/B RxL inhibitor, CID-078. This trial will explore the drug's efficacy in treating patients with advanced solid tumors, especially those with heightened E2F transcription factor activity. Targeted cancers include small cell lung cancer and various types of breast cancer.
Trial Overview and Expectations
David J. Earp, JD, Ph.D., the CEO of Circle Pharma, expressed enthusiasm about the Investigational New Drug (IND) application for CID-078 being approved. He revealed that this approval has allowed the compound to transition into human trials at esteemed cancer centers. These trials aim to gather critical clinical proof-of-concept data, assessing CID-078’s potential to address substantial medical needs.
CID-078 works by selectively inhibiting essential protein interactions between cyclins A and B, both crucial for cancer cell growth and survival. This approach is based on groundbreaking research by Nobel Laureate William G. Kaelin Jr., MD, who explored the concept of synthetic lethality concerning cyclin disruptions. By targeting these pathways, Circle Pharma hopes to offer new hope to patients suffering from resistant cancers.
Insights from Experts
The opinion of Geoffrey Shapiro, MD, Ph.D., from the Dana-Farber Cancer Institute, adds credibility to the urgent need for CID-078. He highlighted the significance of targeting E2F-driven cancer cells and emphasized the lack of selective therapeutic agents until now. The anticipation surrounding Circle Pharma’s progress into clinical settings illustrates the excitement within the cancer research community.
Clinical Trial Design
The Phase 1 trial (NCT06577987) is designed as an open-label, multi-center study, aiming to recruit up to 100 patients. Investigators will assess the safety, pharmacokinetics, and preliminary anti-tumor efficacy of CID-078 across various solid tumors. According to Circle Pharma, initial findings on safety and anti-tumor activity are expected to be disclosed in the near future.
About CID-078
CID-078 represents a groundbreaking investigational therapy specifically formulated to be orally bioavailable. This agent is envisioned to precisely target tumor cells with oncogenic changes leading to cell cycle dysregulation. Earlier studies have supported the potential of these cyclin inhibitors in achieving significant tumor regression in preclinical models, establishing a strong rationale for advancing CID-078 into further clinical assessments.
Circle Pharma's Vision
Circle Pharma is not merely focusing on short-term goals; they are committed to redefining therapeutic possibilities for patients. Based in South San Francisco, the company’s innovative MXMO™ platform integrates structure-based drug design with advanced synthetic chemistry. This unique approach aims to develop macrocycle therapies that are not only effective but also accessible through various administration routes, including oral intake.
Moreover, their focus is primarily on targeting cyclins, which play a pivotal role in regulating cell cycle progression—a crucial factor in many cancer types. The dedication to unearthing transformative treatments illustrates Circle Pharma's commitment to addressing unmet medical needs in oncology.
Frequently Asked Questions
What is CID-078?
CID-078 is a first-in-class oral cyclin A/B RxL inhibitor developed by Circle Pharma, targeting advanced solid tumors.
What types of cancer is CID-078 being tested on?
The clinical trial focuses on cancers such as small cell lung cancer and specific breast cancer types like triple-negative and ER+ HER-2- breast cancer.
How many patients will be enrolled in the trial?
Up to 100 patients are expected to be enrolled in the open-label Phase 1 clinical trial.
What are the goals of the Phase 1 trial?
The trial aims to evaluate the safety, pharmacokinetics, and preliminary anti-tumor activity of CID-078.
When are preliminary results expected to be released?
Circle Pharma anticipates reporting preliminary safety and anti-tumor activity data from the trial in the future.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
Disclaimer: The content of this article is solely for general informational purposes only; it does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice; the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. The author's interpretation of publicly available data shapes the opinions presented here; as a result, they should not be taken as advice to purchase, sell, or hold any securities mentioned or any other investments. The author does not guarantee the accuracy, completeness, or timeliness of any material, providing it "as is." Information and market conditions may change; past performance is not indicative of future outcomes. If any of the material offered here is inaccurate, please contact us for corrections.
Related Articles
- Microbot Medical Advances Clinical Trials and FDA Plans
- Orion Group's Resilience in the Face of Hurricane Milton's Impact
- BofA Maintains Confidence in Biohaven's Growth Potential
- Albertsons Surpasses Q2 Earnings with Boost in Digital Sales
- MTU Aero Engines Surges Ahead with Increased 2024 Outlook
- 89bio Announces Findings from ENLIVEN Study Ahead of AASLD 2024
- ADS-TEC Energy Optimizes Leadership with New CFO Appointment
- Hyphenate Revolutionizes Sales Proposals with AI Technology
- Join scPharmaceuticals for an Insightful KOL Webinar Event
- Revolutionizing Law Enforcement Investigations with AI Solutions
Recent Articles
- Viasat Chooses ST Engineering iDirect for Enhanced Connectivity
- FPX Nickel Achieves Significant Milestone in Nickel Sulphate Production
- State Street Corporation Shows Strong Performance in Q3 2024
- Iridium's Partnership with SDA: A Leap into Satellite Innovations
- G Mining Ventures Releases New Technical Report for Oko West
- EDITED Welcomes Mike MacKeen as New CFO to Drive Growth
- Gogo Business Aviation Unveils Nationwide Tour for Galileo
- Bank of America Shares Strong Third-Quarter Performance Insights
- Integra Connect Partners with Jaan and Sweeten Health for Oncology
- Ericsson Reports Impressive Q3 Gains with AT&T Partnership Insights
- The SEER Group Partners with Interplay for Enhanced Employee Training
- Lutris Pharma Reaches Key Milestone in LUT014 Clinical Trial
- Community-Driven Partnership of Harts Plumbers and Kraken
- Cyngn Partners with Raymond West to Sell Autonomous Tugger
- Gan & Lee Pharmaceuticals Shows Promising Results in T2D Trials
- Shell Faces Major Legal Challenges in Russia Amid Oil Industry Shifts
- Pfizer Welcomes Tim Buckley to the Board - A New Era Ahead
- Teledyne Technologies Unveils Advanced Counter-Drone Solution
- Etsy Faces Downgrade and New Challenges Ahead to Navigate
- Wells Fargo reaffirms positive outlook for Nurix Therapeutics
- Wells Fargo Shares Upgraded: A Dive into Future Earnings Potential
- DHT Holdings Sees Bright Future with VLCC Rate Surge and Dividends
- Goldman Sachs Optimistic on Risky Assets Amid Strong Growth
- Market Awaits Big Bank Earnings While Stocks Pause Rally
- Boeing Aims to Raise $25 Billion Through Stock and Debt Sales
- Bank of America Faces Profit Decline Amid Interest Rate Pressures
- Robert Kiyosaki's Insights on Navigating Financial Challenges
- Supermicro vs. Dell: The Future of AI Server Dominance
- Discover Exciting Growth Opportunities in Budget Stocks
- Simplifying Your Investment Strategy with Dividend ETFs
- Chevron: A High-Yield Stock to Consider For Long-Term Growth
- Johnson & Johnson Raises 2024 Profit Outlook After Solid Q3
- Water Sports Products Market Expected to Surpass $58 Billion
- Mobilicom Highlights Cutting-Edge Drone Solutions at AUSA
- Steakholder Foods' Path to Revenue Growth and Innovation
- Eternal's Strategic Innovations for Global Entertainment Growth
- Beamr and Bridge Digital Innovations in Video Distribution
- Innovations in Orthopedic Robots: Shaping Future Surgeries
- DexCom, Inc. Investors Urged to Join Securities Fraud Class Action
- Projecting Strong Growth for the Narcolepsy Market Ahead
- DT Midstream's Upcoming Earnings Call and Business Growth
- Legal Action Against Super Micro Computer: What Investors Need to Know
- Pharvaris Invites Investors to Discuss HAE Treatment Developments
- Toronto-Dominion Bank Faces Investigation for Alleged Fraud
- Teledyne FLIR Defense Launches the Innovative Cerberus XL System
- PNC Financial Services' Q3 2024 Results: A Profitable Quarter
- Elanco Animal Health Faces Legal Challenge Over Fraud Allegations
- Tim Buckley Joins Pfizer's Board to Drive Innovation Forward
- Transforming Customer Service: eGain Solve 2024 Conference Insights
- MultiBank Group Sets New Standards with Recent Award Win